Thymosin alpha-1

A 28 amino acid thymic peptide that modulates T cell responses, licensed as a medicine in some countries and not approved in the United States.

What it is

Thymosin alpha-1 is a naturally occurring peptide, originally isolated from thymus tissue, made of 28 amino acids. It acts largely through toll-like receptor signaling on dendritic cells, which shifts T cell maturation and cytokine output.

Unlike most peptides sold online, it has a genuine regulatory history. A synthetic version is licensed in more than 30 countries, mainly for chronic hepatitis B and as an adjuvant in some cancer protocols. It is not FDA approved in the United States.

What the human evidence covers

The strongest data sit in specific clinical populations: chronic viral hepatitis, sepsis, and patients whose immune function is measurably suppressed. A randomized Chinese trial in severe sepsis reported reduced 28 day mortality, and it was studied during COVID-19 for the same reason.

What that record does not include is healthy adults taking it to boost immunity or slow aging. In an immune system that is working normally, more T cell activation is not automatically better, and autoimmune conditions are the obvious caution.

How it differs from thymosin beta-4

The names are close and the molecules are unrelated. Thymosin alpha-1 is immune signaling. Thymosin beta-4 is an actin binding protein involved in cell migration and tissue repair, and is the parent of the fragment sold as TB-500.

Baseline does not dispense this. It is here because people ask about it, and because an honest read of the evidence is more useful than a sales page.

References

  1. Camerini R, Garaci E. Historical review of thymosin alpha 1 in infectious diseases. Expert Opin Biol Ther. 2015.
  2. Wu J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. 2013.
  3. Matteucci C, et al. Thymosin alpha 1 mitigates cytokine storm in blood cells from coronavirus disease 2019 patients. Open Forum Infect Dis. 2021.